Table 1. Subjects clinical characteristics.
| Apixaban | Dabigatran | Rivaroxaban | Non-DOAC | |
|---|---|---|---|---|
| n = 50 | n = 62 | n = 53 | n = 24 | |
| Mean age in years (SD) | 72 (10.3) | 70.9 (9.1) | 70.8 (11.9) | 48 (11.6) |
| Gender n (%) |
||||
| Female | 25 (50) | 24 (39) | 25 (47) | 16 (67) |
| Male | 25 (50) | 38 (61) | 28 (53) | 8 (33) |
| Ethnicity n (%) |
||||
| Caucasian | 44 (88) | 59 (95) | 49 (92) | 21 (88) |
| Other | 6 (12) | 3 (5) | 4 (8) | 3 (12) |
| DOAC indication n (%) |
||||
| Atrial fibrillation or flutter | 43 (86) | 62 (100) | 45 (85) | |
| DVT/PE treatment | 4 (8) | 0 | 6 (11) | |
| DVT prophylactic | 3 (6) | 0 | 2 (4) | |
| Comorbidities n (%) |
||||
| Hyperlipidemia | 27(54) | 37 (60) | 24 (45) | 5 (21) |
| Hypertension | 38 (76) | 43 (69) | 33 (62) | 10 (42) |
| Heart failure | 14 (28) | 7 (11) | 6 (11) | |
| Diabetes | 12 (24) | 16 (26) | 8 (15) | |
| Hypothyroidism | 4 (8) | 8 (13) | 6 (11) | 1 (4) |
| Coronary artery disease | 3 (6) | 6 (10) | 10 (19) | |
| Antiplatelet therapy ConMed n (%) |
||||
| Aspirin | 9 (18) | 17 (27) | 10 (19) | 2 (8) |
| Clopidogrel | 4 (8) | 1 (2) | 1 (2) | |
| Prasugrel | 1 (2) | |||
Abbreviations: DOAC, direct-acting oral anticoagulants; DVT, deep vein thrombosis; PE, pulmonary embolism; SD, standard deviation.